Literature DB >> 23869942

Immunohistochemical analysis of ubiquilin-1 in the human hippocampus: association with neurofibrillary tangle pathology.

Katsuyoshi Mizukami1, Eric E Abrahamson, Zhiping Mi, Masanori Ishikawa, Kazushi Watanabe, Setsuo Kinoshita, Takashi Asada, Milos D Ikonomovic.   

Abstract

This post mortem immunohistochemical study examined the localization and distribution of ubiquilin-1 (UBL), a shuttle protein which interacts with ubiquitin and the proteasome, in the hippocampus from Alzheimer's disease (AD) dementia cases, and age-matched cases without dementia. In Braak stages 0-I-II cases, UBL immunoreactivity was detected in a dense fiber network in the neuropil, and in the cell cytoplasm and nucleoplasm of neurons in Cornu Ammonis (CA) fields and dentate gyrus granular neurons. In Braak stages III-IV and V-VI cases, UBL immunoreactivity was reduced in the neuropil and in the cytoplasm of the majority of CA1 neurons; some CA1 pyramidal neurons and the majority of CA2/3 pyramidal, CA4 multipolar, and dentate granular neurons had markedly increased UBL immunoreactivity in the nucleoplasm. Dual immunofluorescence analysis of UBL and antibody clone AT8 revealed co-localization most frequently in CA1 pyramidal neurons in Braak stage III-IV and V-VI cases. Further processing using the pan-amyloid marker X-34 revealed prominent UBL/X-34 dual labeling of extracellular NFT confined to the CA1/subiculum in Braak stage V-VI cases. Our results demonstrate that in AD hippocampus, early NFT changes are associated with neuronal up-regulation of UBL in nucleoplasm, or its translocation from the cytoplasm to the nucleus. The perseverance of UBL changes in CA2/3, CA4 and dentate gyrus, generally considered as more resistant to NFT pathology, but not in the CA1, may mark a compensatory, potentially protective response to increased tau phosphorylation in hippocampal neurons; the failure of such a response may contribute to neuronal degeneration in end-stage AD.
© 2013 Japanese Society of Neuropathology.

Entities:  

Keywords:  Alzheimer; Plic-1; amyloid; tau; ubiquilin

Mesh:

Substances:

Year:  2013        PMID: 23869942      PMCID: PMC4000263          DOI: 10.1111/neup.12055

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  25 in total

1.  Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes.

Authors:  M Mercken; M Vandermeeren; U Lübke; J Six; J Boons; A Van de Voorde; J J Martin; J Gheuens
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

2.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

3.  Immunohistochemical study of GABA(A) receptor beta2/3 subunits in the hippocampal formation of aged brains with Alzheimer-related neuropathologic changes.

Authors:  K Mizukami; M D Ikonomovic; D R Grayson; R T Rubin; D Warde; R Sheffield; R L Hamilton; P Davies; D M Armstrong
Journal:  Exp Neurol       Date:  1997-10       Impact factor: 5.330

Review 4.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

Review 5.  Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group.

Authors: 
Journal:  Neurobiol Aging       Date:  1998 Mar-Apr       Impact factor: 4.673

6.  KP-1 is a marker for extraneuronal neurofibrillary tangles and senile plaques in Alzheimer diseased brains.

Authors:  K Kobayashi; F Muramori; T Aoki; M Hayashi; K Miyazu; Y Fukutani; M Mukai; F Koshino
Journal:  Dement Geriatr Cogn Disord       Date:  1998 Jan-Feb       Impact factor: 2.959

7.  Family-based association between Alzheimer's disease and variants in UBQLN1.

Authors:  Lars Bertram; Mikko Hiltunen; Michele Parkinson; Martin Ingelsson; Christoph Lange; Karunya Ramasamy; Kristina Mullin; Rashmi Menon; Andrew J Sampson; Monica Y Hsiao; Kathryn J Elliott; Gonül Velicelebi; Thomas Moscarillo; Bradley T Hyman; Steven L Wagner; K David Becker; Deborah Blacker; Rudolph E Tanzi
Journal:  N Engl J Med       Date:  2005-03-03       Impact factor: 91.245

8.  Changes in hippocampal GABABR1 subunit expression in Alzheimer's patients: association with Braak staging.

Authors:  Masahiko Iwakiri; Katsuyoshi Mizukami; Milos D Ikonomovic; Masanori Ishikawa; Shin Hidaka; Eric E Abrahamson; Steven T DeKosky; Takashi Asada
Journal:  Acta Neuropathol       Date:  2005-03-10       Impact factor: 17.088

Review 9.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

10.  Ubiquilin 1 polymorphisms are not associated with late-onset Alzheimer's disease.

Authors:  Scott Smemo; Petra Nowotny; Anthony L Hinrichs; John S K Kauwe; Sara Cherny; Katherine Erickson; Amanda J Myers; Mona Kaleem; Lauren Marlowe; Alison M Gibson; Paul Hollingworth; Michael C O'Donovan; Chris M Morris; Peter Holmans; Simon Lovestone; John C Morris; Leon Thal; Yonghong Li; Andrew Grupe; John Hardy; Michael J Owen; Julie Williams; Alison Goate
Journal:  Ann Neurol       Date:  2006-01       Impact factor: 10.422

View more
  6 in total

1.  Overexpression of Ubiquilin-1 Alleviates Alzheimer's Disease-Caused Cognitive and Motor Deficits and Reduces Amyloid-β Accumulation in Mice.

Authors:  Oludotun O Adegoke; Fangfang Qiao; Yanying Liu; Kirsty Longley; Shelley Feng; Hongmin Wang
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

2.  Alzheimer's Disease and Protein Kinases.

Authors:  Ayse Basak Engin; Atilla Engin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Nuclear and cytoplasmic huntingtin inclusions exhibit distinct biochemical composition, interactome and ultrastructural properties.

Authors:  Nathan Riguet; Anne-Laure Mahul-Mellier; Niran Maharjan; Johannes Burtscher; Marie Croisier; Graham Knott; Janna Hastings; Alice Patin; Veronika Reiterer; Hesso Farhan; Sergey Nasarov; Hilal A Lashuel
Journal:  Nat Commun       Date:  2021-11-12       Impact factor: 14.919

4.  Disrupting the Balance of Protein Quality Control Protein UBQLN2 Accelerates Tau Proteinopathy.

Authors:  Julia E Gerson; Stephanie Sandoval-Pistorius; Jacqueline P Welday; Aleija Rodriguez; Jordan D Gregory; Nyjerus Liggans; Kylie Schache; Xingli Li; Hanna Trzeciakiewicz; Sami Barmada; Lisa M Sharkey; Henry L Paulson
Journal:  J Neurosci       Date:  2022-01-26       Impact factor: 6.709

Review 5.  Taking aim at Alzheimer's disease through the mammalian target of rapamycin.

Authors:  Kenneth Maiese
Journal:  Ann Med       Date:  2014-08-08       Impact factor: 4.709

6.  Reduced body weight gain in ubiquilin-1 transgenic mice is associated with increased expression of energy-sensing proteins.

Authors:  Fangfang Qiao; Kirsty R Longley; Shelley Feng; Sabrina Schnack; Hongbo Gao; Yifan Li; Evelyn H Schlenker; Hongmin Wang
Journal:  Physiol Rep       Date:  2017-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.